Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides

Brain Research Reviews

Volumn 55, Issue 1, 2007, Pages 144-154

  Ferraro, Luca ^a   Tomasini, Maria C ^a   Fuxe, Kjell ^b   Agnati, Luigi F ^c   Mazza, Roberta ^a   Tanganelli, Sergio ^a   Antonelli, Tiziana ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Dopamine; GABA; Glutamate release; Intracellular communication; Mesolimbic dopamine system; Nucleus accumbens; Psychostimulants; Receptor receptor interaction; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; COCAINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; NEUROLEPTIC AGENT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTRANSMITTER; PSYCHOSTIMULANT AGENT; RECEPTOR SUBTYPE;

4 AMINOBUTYRIC ACID RELEASE; BIOCHEMISTRY; BRAIN; BRAIN CORTEX; BRAIN REGION; COCAINE DEPENDENCE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; GLOBUS PALLIDUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMBIC SYSTEM; MAMMAL; MESOLIMBIC DOPAMINERGIC SYSTEM; MOLECULAR DYNAMICS; MORPHOLOGY; NEUROANATOMY; NEUROCHEMISTRY; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; REWARD; SCHIZOPHRENIA; SENSORY NERVE; SIGNAL TRANSDUCTION; TARGET VARIABLE;

AFFERENT PATHWAYS; ANIMALS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; GLUTAMATES; NEOSTRIATUM; NEUROTENSIN; NUCLEUS ACCUMBENS;

EID: 34548804335     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2007.03.006     Document Type: Review

References (129)

1. Adell A., and Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci. Biobehav. Rev. 28 (2004) 415-431
2. Agnati L.F., Fuxe K., Benfenati F., and Battistini N. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites. Acta Physiol. Scand. 119 (1983) 459-461
3. Agnati L.F., Fuxe K., Zoli M., Ozini I., Toffano G., and Ferraguti F. A correlation analysis of the regional distribution of central enkephalin and beta-endorphin immunoreactive terminals and of opiate receptors in adult and old male rats. Evidence for the existence of two main types of communication in the central nervous system: the volume transmission and the wiring transmission. Acta Physiol. Scand. 128 (1986) 201-207
4. Agnati L.F., Leo G., Zanardi A., Genedani S., Rivera A., Fuxe K., and Guidolin D. Volume transmission and wiring transmission from cellular to molecular networks: history and perspectives. Acta Physiol. (Oxf.) 187 (2006) 329-344
5. Alexander M.J., and Leeman S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J. Comp. Neurol. 402 (1998) 475-500
6. Berger B., Gaspar P., and Verney C. Colocalization of neurotensin in the mesocortical dopaminergic system. Restricted regional and laminar distribution in rat, lack of colocalization in human. Ann. N. Y. Acad. Sci. 668 (1992) 307-310
7. Betancur C., Lepee-Lorgeoux I., Cazillis M., Accili D., Fuchs S., and Rostène W. Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D(3) receptor deficient mice. Neuropsychopharmacology 24 (2001) 170-182
8. Binder E.B., Kinkead B., Owens M.J., and Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol. Rev. 53 (2001) 453-486
9. Boudin H., Pélaprat D., Rostène W., and Beaudet A. Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J. Comp. Neurol. 373 (1996) 76-89
10. Boules M., Fredrickson P., and Richelson E. Neurotensin agonists as an alternative to antipsychotics. Expert Opin. Invest. Drugs 14 (2005) 359-369
11. Boules M., Shaw A., Fredrickson P., and Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21 (2007) 13-23
12. Brog J.S., Salyapongse A., Deutch A.Y., and Zahm D.S. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J. Comp. Neurol. 338 (1993) 255-278
13. Caceda R., Kinkead B., and Nemeroff C.B. Neurotensin: role in psychiatric and neurological diseases. Peptides 27 (2006) 2385-2404
14. Carlsson A., Waters N., and Carlsson M. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry 46 (1999) 1388-1395
15. Carraway R., and Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248 (1973) 6854-6861
16. Cooper P.E., Fernstrom M.H., and Rorstad O.P. The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res. 218 (1981) 219-232
17. Costa F.G., Frussa-Filho R., and Felicio L.F. The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. Eur. J. Pharmacol. 428 (2001) 97-103
18. Chapman M.A., and See R.E. The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats. Brain Res. 729 (1996) 124-126
19. Chen L., Yung K.K., and Yung W.H. Neurotensin selectively facilitates glutamatergic transmission in globus pallidus. Neuroscience 141 (2006) 1871-1878
20. Dallvechia-Adams S., Smith Y., and Kuhar M.J. CART peptide-immunoreactive projection from the nucleus accumbens targets substantia nigra pars reticulata neurons in the rat. J. Comp. Neurol. 434 (2001) 29-39
21. Del Arco A., Segovia G., Fuxe K., and Mora F. Changes in dialysate concentrations of glutamate and GABA in the brain: an index of volume transmission mediated actions?. J. Neurochem. 85 (2003) 23-33
22. Delle Donne K.T., Sesack S.R., and Pickel V.M. Ultrastructural immunocytochemical localization of neurotensin and the dopamine D2 receptor in the rat nucleus accumbens. J. Comp. Neurol. 371 (1996) 552-566
23. Dobner P.R. Multitasking with neurotensin in the central nervous system. Cell. Mol. Life Sci. 62 (2005) 1946-1963
24. Dobner P.R., Deutch A.Y., and Fadel J. Neurotensin: dual roles in psychostimulant and antipsychotic drug responses. Life Sci. 73 (2003) 801-811
25. Drew K.L., O'Connor W.T., Kehr J., and Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol. 187 (1990) 385-397
26. Emson P.C., Goedert M., Horsfield P., Rioux F., and St Pierre S. The regional distribution and chromatographic characterisation of neurotensin-like immunoreactivity in the rat central nervous system. J. Neurochem. 38 (1982) 992-999
27. Everitt B.J., and Wolf M.E. Psychomotor stimulant addiction: a neural systems perspective. J. Neurosci. 22 (2002) 3312-3320
28. Fadel J., Dobner P.R., and Deutch A.Y. Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice. Neurosci. Lett. 402 (2006) 97-101
29. Faggin B.M., Zubieta J.K., Rezvani A.H., and Cubeddu L.X. Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. J. Pharmacol. Exp. Ther. 252 (1990) 817-825
30. + conductance in rat midbrain dopaminergic neurons. Neurosci. Lett. 231 (1997) 21-24
31. Fassio A., Evans G., Grisshammer R., Bolam J.P., Mimmack M., and Emson P.C. Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology 39 (2000) 1430-1442
32. Ferraro L., O'Connor W.T., Antonelli T., Fuxe K., and Tanganelli S. Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat. Eur. J. Neurosci. 9 (1997) 1838-1846
33. Ferraro L., Antonelli T., O'Connor W.T., Fuxe K., Soubriè P., and Tanganelli S. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J. Neurosci. 18 (1998) 6977-6989
34. Ferraro L., Tomasini M.C., Siniscalchi A., Fuxe K., Manganelli S., and Antonelli T. Neurotensin increases endogenous glutamate release in rat cortical slices. Life Sci. 66 (2000) 927-936
35. Ferraro L., Tomasini M.C., Fernandez M., Bebe B.W., O'Connor W.T., Fuxe K., Glennon J.C., Tanganelli S., and Antonelli T. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. Neuroscience 102 (2001) 113-120
36. Ferrè S., O'Connor W.T., Snaprud P., Ungerstedt U., and Fuxe K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63 (1994) 765-773
37. Fibiger H. Neurobiology of depression: focus on dopamine. Adv. Biochem. Psychopharmacol. 49 (1995) 1-17
38. Fillenz M. In vivo neurochemical monitoring and the study of behaviour. Neurosci. Biobehav. Rev. 29 (2005) 949-962
39. Fredrickson P., Boules M., Lin S.C., and Richelson E. Neurobiologic basis of nicotine addiction and psychostimulant abuse: a role for neurotensin?. Psychiatr. Clin. North Am. 28 (2005) 737-751
40. Frey P., Fuxe K., Eneroth P., and Agnati L.F. Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat. Neurochem. Int. 8 (1986) 429-434
41. Fuxe K., and Agnati L.F. Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 5 (1985) 441-482
42. Fuxe K., O'Connor W.T., Antonelli T., Osborne P.G., Tanganelli S., Agnati L.F., and Ungerstedt U. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc. Natl. Acad. Sci. 89 (1992) 5591-5595
43. Fuxe K., Von Euler G., Agnati L.F., Merlo Pich E., O'Connor W.T., Tanganelli S., Li X.M., Tinner B., Cintra A., and Carani C. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. N. Y. Acad. Sci. 668 (1992) 186-204
44. Fuxe K., Li X.M., Tanganelli S., Hedlund P., O'Connor W.T., Ferraro L., Ungerstedt U., and Agnati L.F. Receptor-receptor interactions and their relevance for receptor diversity. Focus on neuropeptide/dopamine interactions. Ann. N. Y. Acad. Sci. 757 (1995) 365-376
45. Fuxe K., Manger P., Genedani S., and Agnati L. The nigrostriatal DA pathway and Parkinson's disease. J. Neural Transm., Suppl. 70 (2006) 71-83
46. Geisler S., and Zahm D.S. Neurotensin afferents of the ventral tegmental area in the rat: [1] re-examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration. Eur. J. Neurosci. 24 (2006) 116-134
47. Geisler S., Berod A., Zahm D.S., and Rostène W. Brain neurotensin, psychostimulants, and stress-emphasis on neuroanatomical substrates. Peptides 27 (2006) 2364-2384
48. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15 (1992) 133-139
49. Groenewegen H.J., Berendse H.W., Meredith G.E., Haber S.N., Voorn P., Wolters J.G., and Lohman A.H.M. In: Willner P., and Scheel-Kruger J. (Eds). The Mesolimbic Dopamine System (1991), Wiley, New York 19-59
50. Groenewegen H.J., Wright C.I., Beijer A.V., and Voorn P. Convergence and segregation of ventral striatal inputs and outputs. Ann. N. Y. Acad. Sci. 877 (1999) 49-63
51. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., and Brouard A. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 65-69
52. Haber S.N., Kunishio K., Mizobuchi M., and Lynd-Balta E. The orbital and medial prefrontal circuit through the primate basal ganglia. J. Neurosci. 15 (1995) 4851-4867
53. Heaulme M., Leyris R., Le Fur G., and Soubriè P. Involvement of potentially distinct neurotensin receptors in neurotensin-induced stimulation of striatal. Neuropharmacology 36 (1997) 1447-1454
54. Heimer L., Alheid G.F., Zahma I., Boireau D.S., Dubedat P., and Blanchard J.C. In: Kalivas P.W., and Barnes C.D. (Eds). Limbic Motor Circuits and Neuropsychiatry (1993), CRC Press, Boca Raton, FL 1-43
55. Hermans E., and Maloteaux J.M. Mechanisms of regulation of neurotensin receptors. Pharmacol. Ther. 79 (1998) 89-104
56. Hetier E., Boireau A., Dubedat P., and Blanchard J.C. Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 337 (1988) 13-17
57. Hökfelt T., Everitt B.J., Theodorsson-Norheim E., and Goldstein M. Occurrence of neurotensin like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol. 222 (1984) 543-559
58. Horger B.A., Taylor J.R., Elsworth J.D., and Roth R.H. Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacology 11 (1994) 215-222
59. Horvitz J.C. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96 (2000) 651-656
60. Hyman S.E., and Malenka R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev., Neurosci. 2 (2001) 695-703
61. Jiang Z.G., Pessia M., and North R.A. Neurotensin excitation of rat ventral tegmental neurones. J. Physiol. (London) 474 (1994) 119-129
62. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Brain Res. Rev. 18 (1993) 75-113
63. Kalivas P.W. Glutamate systems in cocaine addiction. Curr. Opin. Pharmacol. 4 (2004) 23-29
64. Kalivas P.W., and Miller J.S. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens. Brain Res. 300 (1984) 157-160
65. Kinkead B., and Nemeroff C.B. Neurotensin: an endogenous antipsychotic?. Curr. Opin. Pharmacol. 2 (2002) 99-103
66. Kinkead B., and Nemeroff C.B. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol. Disord. Drug Targets 5 (2006) 205-218
67. Kinkead B., Binder E.B., and Nemeroff C.B. Does neurotensin mediate the effects of antipsychotic drugs?. Biol. Psychiatry 46 (1999) 340-351
68. Kislauskis E., Bullock B., McNeil S., and Dobner P.R. The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences. J. Biol. Chem. 263 (1988) 4963-4968
69. Kitabgi P. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases. Peptides 27 (2006) 2515-2522
70. Kitabgi P., Carraway R., and Leeman S.E. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J. Biol. Chem. 251 (1976) 7053-7058
71. Legault M., Congar P., Michel F.J., and Trudeau L.E. Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones. Neuroscience 111 (2002) 177-187
72. Li X.M., Ferraro L., Tanganelli S., O'Connor W.T., Hasselrot U., Ungerstedt U., and Fuxe K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J. Neural Transm.: Gen. Sect. 102 (1995) 125-137
73. Lopak V., and Erb S. Activation of central neurotensin receptors reinstates cocaine seeking in the rat: modulation by a D1/D5, but not D2/D3, receptor antagonist. Psychopharmacology (Berlin) 182 (2005) 297-304
74. Matsuyama S., Fukui R., Higashi H., and Nishi A. Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling. Eur. J. Neurosci. 18 (2003) 1247-1253
75. Mazella J., and Vincent J.P. Functional roles of the NTS2 and NTS3 receptors. Peptides 27 (2006) 2469-2475
76. Mazella J., and Vincent J.P. Internalization and recycling properties of neurotensin receptors. Peptides 27 (2006) 2488-2492
77. McBride W.J., Murphy J.M., and Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav. Brain Res. 101 (1999) 129-152
78. Merchant K.M. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol. Cell. Neurosci. 5 (1994) 336-344
79. Mercuri N.B., Stratta F., Calabresi P., and Bernardi G. Neurotensin induces an inward current in rat mesencephalic dopaminergic neurons. Neurosci. Lett. 153 (1993) 192-196
80. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78 (1998) 189-225
81. Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic?. Biol. Psychiatry 15 (1980) 283-302
82. Nemeroff C.B., and Cain S.T. Neurotensin-dopamine interactions in the CNS. Trends Pharmacol. Sci. 6 (1985) 201-205
83. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59 (2006) 1151-1159
84. Nicot A., Rostène W., and Bérod A. Neurotensin receptor expression in the rat forebrain and midbrain: a combined in situ hybridization and receptor radioautography study. J. Comp. Neurol. 341 (1994) 407-419
85. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 67 (2002) 53-83
86. Nouel D., Sarret P., Vincent J.P., Mazella J., and Beaudet A. Pharmacological, molecular and functional characterization of glial neurotensin receptors. Neuroscience 94 (1999) 1189-1197
87. O'Connor W.T. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J. Neurosci. Methods 109 (2001) 31-39
88. O'Donnell P., and Grace A.A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr. Bull. 24 (1998) 267-283
89. Osborne P.G., O'Connor W.T., Beck O., and Ungerstedt U. Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Res. 634 (1994) 20-30
90. Panayi F., Colussi-Mas J., Lambas-Senas L., Renaud B., Scarna H., and Berod A. Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization. Neuropsychopharmacology 30 (2005) 871-879
91. Pelaprat D. Interactions between neurotensin receptors and G proteins. Peptides 27 (2006) 2476-2487
92. Pennartz C.M., Groenewegen H.J., and Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 42 (1994) 719-761
93. Petrie K.A., Schmidt D., Bubser M., Fadel J., Carraway R.E., and Deutch A.Y. Neurotensin activates GABAergic interneurons in the prefrontal cortex. J. Neurosci. 25 (2005) 1629-1636
94. Pickel V.M., Chan J., Delle Donne K.T., Boudin H., Pelaprat D., and Rostène W. High-affinity neurotensin receptors in the rat nucleus accumbens: subcellular targeting and relation to endogenous ligand. J. Comp. Neurol. 435 (2001) 142-155
95. Quirion R., Rowe W.B., Lapchak P.A., Araujo D.M., and Beaudet A. Distribution of neurotensin receptors in mammalian brain. What it is telling us about its interactions with other neurotransmitter systems. Ann. N. Y. Acad. Sci. 668 (1992) 109-119
96. Richelson E., Boules M., and Fredrickson P. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Life Sci. 73 (2003) 679-690
97. Romprè P.P., Bauco P., and Gratton A. Facilitation of brain stimulation reward by mesencephalic injections of neurotensin-(1-13). Eur. J. Pharmacol. 211 (1992) 295-303
98. Saleem M.N., Surmeier D.J., and Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens Ann. Rev. Neurosci. 23 (2000) 185-215
99. Saleh T.M., Kombian S.B., Zidichouski J.A., and Pittman Q.J. Cholecystokinin and neurotensin inversely modulate excitatory synaptic transmission in the parabrachial nucleus in vitro. Neuroscience 77 (1997) 23-35
100. Sanz B., Exposito I., and Mora F. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. NeuroReport 4 (1993) 1194-1196
101. Sarret P., Krzywkowski P., Segal L., Nielsen M.S., Petersen C.M., Mazella J., Stroh T., and Beaudet A. Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central nervous system. J. Comp. Neurol. 461 (2003) 483-505
102. Seroogy K.B., Mehta A., and Fallon J.H. Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain. Exp. Brain Res. 68 (1987) 277-289
103. Seutin V., Massotte L., and Dresse A. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro. Neuropharmacology 28 (1989) 949-954
104. St-Gelais F., Legault M., Bourque M.J., Rompré P.P., and Trudeau L.E. Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J. Neurosci. 24 (2004) 2566-2574
105. St-Gelais F., Jomphe C., and Trudeau L.E. The role of neurotensin in central nervous system pathophysiology: what is the evidence. J. Psychiatry. Neurosci. 31 (2006) 229-245
106. Studler J.M., Kitabgi P., Tramu G., Herve D., Glowinski J., and Tassin J.P. Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides 11 (1988) 95-100
107. Tanaka K., Masu M., and Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4 (1990) 847-854
108. Tanganelli S., von Euler G., Fuxe K., Agnati L.F., and Ungerstedt U. Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Brain Res. 502 (1989) 319-324
109. Tanganelli S., Li X.M., Ferraro L., Von Euler G., O'Connor W.T., Bianchi C., Beani L., and Fuxe K. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Eur. J. Pharmacol. 230 (1993) 159-166
110. Tanganelli S., O'Connor W.T., Ferraro L., Bianchi C., Beani L., Ungerstedt U., and Fuxe K. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 60 (1994) 649-657
111. Timmerman W., and Westerink B.H. Brain microdialysis of GABA and glutamate: what does it signify?. Synapse 27 (1997) 242-261
112. Trudeau L.E. Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors. Neuroscience 97 (2000) 293-302
113. Tyler-McMahon B.M., Boules M., and Richelson E. Neurotensin: peptide for the next millennium. Regul. Pept. 93 (2000) 125-136
114. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 63 (2001) 241-320
115. Usuda I., Tanaka K., and Chiba T. Efferent projections of the nucleus accumbens in the rat with special reference to subdivision of the nucleus: biotinylated dextran amine study. Brain Res. 797 (1998) 73-93
116. Villeneuve P., Lafortune L., Seidah N.G., Kitabgi P., and Beaudet A. Immunohistochemical evidence for the involvement of protein convertases 5A and 2 in the processing of pro-neurotensin in rat brain. J. Comp. Neurol. 424 (2000) 461-475
117. Vincent J., Mazzella J., and Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 20 (1999) 302-309
118. Vita N., Oury-Donat F., Chalon P., Guillemot M., Kaghad M., Bachy A., Thurneyssen O., Garcia S., Poinot-Chazel C., Casellas P., Keane P., Le Fur G., Maffrand J.P., Soubriè P., Caput D., and Ferrara P. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur. J. Pharmacol. 360 (1998) 265-272
119. von Euler G., Meister B., Hokfelt T., and Fuxe K. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain. Acta Physiol. Scand. 137 (1989) 309-310
120. von Euler G., Mailleux P., Vanderhaeghen J.J., and Fuxe K. Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen. Neurosci. Lett. 109 (1990) 325-330
121. von Euler G., Meister B., Hokfelt T., Eneroth P., and Fuxe K. Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence. Brain Res. 531 (1990) 253-262
122. von Euler G., van der Ploeg I., Fredholm B.B., and Fuxe K. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. J. Neurochem. 56 (1991) 178-183
123. Wagstaff J.D., Gibb J.W., and Hanson G.R. Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. Brain Res. 721 (1996) 96-203
124. Werkman T.R., Kruse C.G., Nievelstein H., Long S.K., and Wadman W.J. Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area. Neuroscience 95 (2000) 417-423
125. White F.J. Synaptic regulation of mesocorticolimbic dopamine neurons. Annu. Rev. Neurosci. 19 (1996) 405-436
126. Wise R.A. Dopamine, learning and motivation. Nat. Rev., Neurosci. 5 (2004) 483-494
127. Wise R.A. Forebrain substrates of reward and motivation. J. Comp. Neurol. 493 (2005) 115-121
128. Zahm D.S., and Heimer L. Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J. Comp. Neurol. 327 (1993) 220-232
129. Zahm D.S., Williams E., and Wohltmann C. Ventral striatopallidothalamic projection: IV. Relative involvements of neurochemically distinct subterritories in the ventral pallidum and adjacent parts of the rostroventral forebrain. J. Comp. Neurol. 364 (1996) 340-362